United Therapeutics (UTHR) Stock Price, Quote, News & History | Benzinga

United Therapeutics Corp (UTHR) Stock Price, Quote, News & History

UTHRNASDAQ

Trade with Public

Trade with Public

$516.68

-1.85-0.36%

At close: Aug 26, 5:00 PM EST

$516.68

N/A

After Hours: 4:00 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$515.60

Close

$516.68

Volume / Avg.

254.78K / 513.66K

Day Range

$513.98 - $522.02

52 Wk Range

302.19 - 609.35

Market Cap

$21.93B

P/E Ratio

18.58

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

5.82%

Days to Cover

3.52

Recent United Therapeutics Corporation News

United Therapeutics Expands Immune Therapy Pipeline With Thymmune

United Therapeutics (UTHR) acquires Thymmune Therapeutics for $140M upfront, with up to $160M in milestone-based payments.

Vandana Singh

FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs

United Therapeutics received FDA approval for LungFX, a device designed to expand donor lung use in transplantation.

Vandana Singh

Baidu, Brady And 3 Stocks To Watch Heading Into Monday

U.S. stock futures down on Monday. Focus on Baidu, Brady, United Therapeutics for earnings. XP and Ryanair to report after markets close.

Avi Kapoor

Stocks Rise As Powell's Remarks Cool Rate Fears: What's Moving Markets Monday?

U.S. equity markets snap a five-week slide on Monday, bouncing off seven-month lows after President Trump discloses negotiations with a "new and more reasonable" Iranian regime.

Piero Cingari

IQIYI, Compass Diversified, Sigma Lithium And Other Big Stocks Moving Higher On Monday

Dow Jones index up 400 points. IQIYI rose on buyback & HK listing. CODI, UTHR, SGML, CLMT, TRON, AA, BBWI, KOPN, CENX & GEVO gained in session.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.69B

Investing Cash Flow (TTM)

744.50M

Financing Cash Flow (TTM)

-2.22B

Free Cash Flow (TTM)

1.09B

Capital Expenditure (TTM)

-597.70M

Net Change in Cash (TTM)

210.10M

Analyst Trends and Forecast

4

3

Mar

1

Apr

2

May

2

1

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$19.13B

PE Ratio (TTM)

18.58

PE Ratio (FWD)

18.87

PEG Ratio (TTM)

-

PS Ratio (TTM)

7.71

PB Ratio (TTM)

3.48

Earnings Yield % (TTM)

5.38%

Earnings Yield % (FWD)

5.30%

EV / EBITDA (TTM)

11.41

Price / EBITDA (TTM)

14.51

Price / Free Cash Flow (TTM)

22.37

Book Value / Share

$149.22

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$1.80B

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

$0

Key Statistics

Open

$515.60

Close

$516.68

Volume / Avg.

254.78K / 513.66K

Day Range

$513.98 - $522.02

52 Wk Range

302.19 - 609.35

Market Cap

$21.93B

P/E Ratio

18.58

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

5.82%

Days to Cover

3.52

About

Sector

Health Care

Industry

Biotechnology

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy United Therapeutics (UTHR) stock?

A

You can purchase shares of United Therapeutics (NASDAQ:UTHR) through any online brokerage.

View our list of the best stock brokerages

Q

Who are United Therapeutics (UTHR) competitors?

A

Other companies in United Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for United Therapeutics (UTHR) stock?

A

United Therapeutics has a consensus price target of $522.59.

Q

What is the current price for United Therapeutics (UTHR)?

A

The stock price for United Therapeutics (NASDAQ: UTHR) is $516.68 last updated August 26, 2026 at 4:00 PM EDT.

Q

Does United Therapeutics (UTHR) pay a dividend?

A

There are no upcoming dividends for United Therapeutics.

Q

When is United Therapeutics (NASDAQ:UTHR) reporting earnings?

A

United Therapeutics does not have any upcoming earnings scheduled.

Q

Is United Therapeutics (UTHR) going to split?

A

There is no upcoming split for United Therapeutics.

Q

What sector and industry does United Therapeutics (UTHR) operate in?

A

United Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.